Neurocrine taps China biotech for NLRP3 programs: Deals Report

Neurocrine will add a portfolio of NLRP3 programs via a deal with China-based TransThera, adding the closely watched neuroinflammatory target to its pipeline.

TransThera Sciences (Nanjing) Inc. did not disclose the size of the deal’s upfront payment in a regulatory filing, but said the agreement’s total value could rise to $881.5 million, contingent on milestone payments. Its deal with Neurocrine Biosciences Inc. (NASDAQ:NBIX) excludes mainland China, Hong Kong, Macau and Taiwan, but does encompass a research collaboration between the companies...